For the quarter ending 2025-09-30, NWBO had $244K increase in cash & cash equivalents over the period. -$14,095K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -26,829 | -34,721 |
| Depreciation and amortization | 451 | 885 |
| Amortization of debt discount | 414 | 859 |
| Change in fair value of derivatives | -3,332 | 2,004 |
| Change in fair value of share payable | -118 | -263 |
| Change in fair value of convertible notes | -15 | 6,089 |
| Loss from extinguishment of debt | -4,004 | -11,798 |
| Loss from issuance of debt | -1,611 | -773 |
| Amortization of operating lease right-of-use asset | 70 | 130 |
| Stock-based compensation for services | 273 | 749 |
| Subtotal of non-cash charges | 10,288 | 7,364 |
| Prepaid expenses and other current assets | 500 | -111 |
| Other non-current assets | -10 | -3 |
| Accounts payable and accrued expenses | 1,321 | 7,534 |
| Related party accounts payable and accrued expenses | 1,825 | 3,564 |
| Lease liabilities | -8 | 39 |
| Net cash used in operating activities | -13,893 | -16,106 |
| Purchase of equipment and construction in progress | 202 | 397 |
| Loan receivable | 311 | - |
| Net cash used in investing activities | -513 | -397 |
| Proceeds from issuance of common shares | 4,862 | 12,442 |
| Proceeds from exercise of warrants | 0 | 23 |
| Proceeds from issuance of notes payable, net | 0 | 7,000 |
| Proceeds from issuance of convertible notes payable, net | 7,175 | 5,507 |
| Repayment of notes payable | 4 | 255 |
| Repayment of convertible notes payable | 475 | 536 |
| Net cash provided by financing activities | 11,558 | 24,181 |
| Effect of exchange rate changes on cash and cash equivalents | 3,092 | -5,537 |
| Net increase in cash and cash equivalents | 244 | 2,141 |
| Cash and cash equivalents at beginning of period | 2,175 | - |
| Cash and cash equivalents at end of period | 4,560 | - |
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
NORTHWEST BIOTHERAPEUTICS INC (NWBO)